Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?

We analyzed the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI). We retrospectively collected data from 16 worldwide centers involved in the treatment of RCC. Overall survival (OS) and progression-free survival (...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Diagnostics (Basel)
Main Authors: Santoni, Matteo, Massari, Francesco, Bracarda, Sergio, Procopio, Giuseppe, Milella, Michele, De Giorgi, Ugo, Basso, Umberto, Aurilio, Gaetano, Incorvaia, Lorena, Martignetti, Angelo, Rizzo, Mimma, Cartenì, Giacomo, Grande, Enrique, Matrana, Marc R., Crabb, Simon J., Vau, Nuno, Sorgentoni, Giulia, Cimadamore, Alessia, Montironi, Rodolfo, Battelli, Nicola
Formato: Artigo
Idioma:Inglês
Publicado: MDPI 2021
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7831923/
https://ncbi.nlm.nih.gov/pubmed/33477676
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/diagnostics11010138
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares